NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression TherapyTheNewswire • 03/16/26
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline ResultsGlobeNewsWire • 03/11/26
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseTheNewswire • 03/11/26
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver DiseaseGlobeNewsWire • 03/10/26
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board ApprovalGlobeNewsWire • 03/04/26
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?PRNewsWire • 02/19/26
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical TrialGlobeNewsWire • 02/09/26
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAIGlobeNewsWire • 02/06/26
Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative TreatmentsGlobeNewsWire • 02/03/26
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025GlobeNewsWire • 01/20/26
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100GlobeNewsWire • 01/14/26
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 12/31/25
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future GrowthGlobeNewsWire • 12/24/25
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100GlobeNewsWire • 12/16/25
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder TreatmentGlobeNewsWire • 12/12/25
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementGlobeNewsWire • 12/12/25
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price NotificationGlobeNewsWire • 12/05/25
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use DisorderGlobeNewsWire • 12/02/25
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical TrialGlobeNewsWire • 12/01/25
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder TrialGlobeNewsWire • 11/25/25
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety ReviewGlobeNewsWire • 11/24/25
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical SiteGlobeNewsWire • 11/20/25
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for DepressionTheNewswire • 11/19/25